

Approved for use through 07/31/2006. OMB 0651-0031 U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (Use as many sheets as necessary)		Application Number	10/517,869
		Filing Date	October 12, 2005
		First Named Inventor	Anders Lehmann
		Art Unit	1614
		Examiner Name	<del>Louisa Ann A.</del> Spivack
Sheet	1	of	1
		Attorney Docket Number	1103326-0946

**U.S. PATENT DOCUMENTS**

Examiner Initials <sup>a</sup>	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages/Figures Appear

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>a</sup>	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>2</sup> -Number <sup>3</sup> -Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T <sup>6</sup>

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials <sup>a</sup>	Cite No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T
/P.S./		HORNBY ET AL., "Receptors and Transmission in the Brain-Gut Axis II. Excitatory amino acid receptors in the brain-gut axis", The Am. J. Physiological Society, 280: G1055-G1060, 2001.	
/P.S./		LEHMANN ET AL., "Effects of antagonism of NMDA receptors on transient lower esophageal sphincter relaxations in the dog", European J. of Pharm. 431:253-258, 2001.	
/P.S./		O'LEARY ET AL., "Selective mGluR5 antagonists MPEP and SIB-1893 decrease NMDA or glutamate-mediated neuronal toxicity through actions that reflect NMDA receptor antagonism", British J. of Pharm. 131:1429-1437, 2000.	
/P.S./		LIU ET AL., "Agonist- and Reflex-Evoked Internalization of Metabotropic Glutamate Receptor 5 in Enteric Neurons", The J. of Neuroscience, 20(9):3200-3205, May 1, 2000.	
/P.S./		BLACKSHAW ET AL., "Gastrointestinal pharmacology-new therapeutic vistas", Current Opinion in Pharm. 1:561-562, 2001.	
/P.S./		KIRCHGESSNER, A., "Glutamate in the enteric nervous system", Current Opinion in Pharm. 1:591-596, 2001	
/P.S./		J. T. GREENAMYRE ET AL., "Anatomy and physiology of glutamate in the CNS", Neurology 44 (Suppl. 8), Nov., S7-S13, 1994.	
/P.S./		D. P. HIRSCH ET AL., "Involvement of Glutamate to Transient Lower Esophageal Sphincter Relaxations in Man", Gastroenterology 120, A-630 (3197), 2001.	
/P.S./		J. A. SAUGSTAD ET AL., "L-2-amino-3-phosphonopropionic acid competitively antagonizes metabotropic glutamate receptors 1a and 5 in <i>Xenopus</i> oocytes", Euro. J. of Pharm. 289:395-397, 1995.	
/P.S./		A. E. KINGSTON ET AL., "Pharmacological Analysis of 4-Carboxyphenylglycine Derivatives: Comparison of Effects on mGluR1a and mGluR5a Subtypes", Neuropharm. Vol. 34, 8:887-894, 1995.	
		<del>Opposition against EP 1 513 525 B1 filed by Addex Pharm SA.</del>	
		<del>Opposition against EP 1 513 525 B1 filed by Novartis AG</del>	
Examiner Signature	/Phyllis Spivack/	Date Considered	09/11/2009

<sup>a</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Date line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Year Office that issued the document, by the two-letter code (WIPO Standard ST 3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbol as indicated on the document under WIPO Standard ST 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language translation is needed. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or assist a benefit by the public which is to file (and the USPTO to process) an application. Confidentiality as governed by 35 U.S.C. 122 and 37 CFR 1.61 and 1.62. This collection is returned to the applicant to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORM TO THIS ADDRESS: SEND TO: Commissioner for Patent, P.O. Box 1450, Alexandria, VA 22313-1450.